Exelixis

Exelixis, developing small molecule therapies for the treatment of cancer. Read more

266 Followers on Owler
266 Followers on Owler
266 Followers on Owler
266 Followers on Owler

Exelixis

Exelixis, developing small molecule therapies for the treatment of cancer. Read more

Michael M. Morrissey's photo - President & CEO of Exelixis

President & CEO

Michael M. Morrissey

CEO Approval Rating

89/100

Founded:

1994

Status:

PublicIndependent CompanyNASDAQEXEL

EXELIXIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Agios is Exelixis's biggest rival. Agios was founded in 2008, and is headquartered in Cambridge, Massachusetts. Agios competes in the Pharmaceuticals industry. Agios generates $784.3M less revenue vs. Exelixis.

Allergan is one of Exelixis's top competitors. Allergan's headquarters is in Coolock, County Dublin, and was founded in 1948. Allergan operates in the Health Care Supplies industry. Allergan generates 1,620% of Exelixis's revenue.

TESARO is seen as one of Exelixis's top competitors. TESARO is a Private company that was founded in 2010 in Waltham, Massachusetts. TESARO is in the Pharmaceuticals field. Compared to Exelixis, TESARO has 231 more employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Monopar a competitor of Exelixis?

Exelixis Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$987.5M

Exelixis's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 6B. Over the last four quarters, Exelixis's revenue has grown by 4.1%. Specifically, in Q2 2021's revenue was $270.2M; in Q1 2021, it was $497M; in Q4 2020, it was $231.1M; in Q3 2020, Exelixis's revenue was $259.5M.

Exelixis Acquisitions

No recent acquisitions found related to Exelixis

Exelixis Funding History

Since Exelixis was founded in 1994, it has participated in 2 rounds of funding. In total Exelixis has raised $118.3M. Exelixis' last funding round was on Jun 2008 for a total of $0

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Jun 2008
--

Deerfield Capital Management

IPO
Apr 2000
$118.3M

Since Exelixis was founded in 1994, it has participated in 2 rounds of funding. In total Exelixis has raised $118.3M. Exelixis' last funding round was on Jun 2008 for a total of $0

Exelixis Investments

No recent investments found related to Exelixis

Exelixis News

April 1, 2021Zacks

Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combina... See more »
March 10, 2021Pharmabiz

Exelixis, WuXi Biologics ink exclusive license agreement to support further expansion of Exelixis' oncology biologics pipeline

WuXi Biologics, a global company with leading open─access biologics technology platforms, and Exelixi... See more »
February 26, 2021MarketScreener

rsquo; Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

(marketscreener.com) - CHMP recommendation follows U.S. FDA approval of CABOMETYX in combination with... See more »
February 25, 2021MarketScreener

to Webcast Fireside Chats as Part of Virtual Investor Conferences in March

(marketscreener.com) Presentations to be webcast on www.exelixis.comhttps://www.marketscreener.com/qu... See more »

Exelixis Press Releases

December 7, 2020Business Wire

Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exe... See more »
December 2, 2020Business Wire

Exelixis In-Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application

ALAMEDA, Calif., SOUTH SAN FRANCISCO, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Exelixis... See more »
November 3, 2020PressReleasePoint

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November

Credit Suisse 29 th Annual Virtual Healthcare Conference : Exelixis is scheduled to present at 4:15 p... See more »
October 22, 2020Business Wire

Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarte... See more »
October 19, 2020Business Wire

U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) in Advanced Renal Cell Carcinoma

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review ... See more »
October 9, 2020PressReleasePoint

Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

The new data will be presented in a poster discussion session (Abstract 33) as part of the 32 nd EORT... See more »
September 15, 2020PressReleasePoint

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that suppo... See more »

Social Media

Exelixis Headquarters

1851 Harbor Bay Parkway

Alameda, California94502

650-837-7000

Driving Directions »

Trending Companies

Exelixis Summary

ABOUT

Overview

Exelixis, developing small molecule therapies for the treatment of cancer. Exelixis was founded in 1994. Exelixis' headquarters is located in Alameda, California, USA 94502. It has raised 118.3M in 2 rounds. The latest round was in Jun 2008. Some of E...

CEO

Exelixis's President & CEO, Michael M. Morrissey, currently has an approval rating of 89%. Exelixis's primary competitors are Agios, Allergan & TESARO.

Website

exelixis.com

Frequently Asked Questions about Exelixis

  1. When was Exelixis founded?

    Exelixis was founded in 1994
  2. Who is Exelixis's CEO?

    Exelixis's CEO is Michael M. Morrissey
  3. How much revenue does Exelixis generate?

    Exelixis generates $987.5M in revenue
  4. How much funding does Exelixis have?

    Exelixis has historically raised $118.3M in funding
  1. Where is Exelixis's headquarters?

    Exelixis's headquarters is in Alameda California, USA
  2. How many employees does Exelixis have?

    Exelixis has 484 employees
  3. Who are Exelixis's competitors?

    Exelixis's top competitors are Agios, Allergan, TESARO